Clinical trials: Uterine Neoplasm
Neoplasms, Endometrial
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants.
- Trial name
- NCT07108270
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
Cervical Cancer
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604) plus chemotherapy in patients with Stage IV, recurrent, or metastatic cervical cancer.
- Trial name
- NCT04864782
- Testing
- QL1604, Paclitaxel injection, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Infections, Papillomavirus
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00306241
- Testing
- HPV-16/18 L1 VLP AS04
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Menorrhagia, Uterine Fibroids
Uterine Artery Occlusion for Fibroid Related Bleeding
The primary objective of this study is to evaluate the safety and effectiveness of Doppler guided Uterine Artery Occlusion (D-UAO) as treatment for the reduction of fibroid-associated symptoms.
- Trial name
- NCT00496067
- Testing
- Doppler-Guided Uterine Artery Occlusion Device
- Where
- 14 sites in Denmark, France and 5 more
- Volunteers
- 91 people
- Sponsor
- Ethicon, Inc.
Endometrial Neoplasms, Endometrium
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Lenvatinib in lenvatinib/pembrolizumab combination therapy in the post marketing setting: (1) Serious…
- Conditions
- Endometrial Neoplasms, Endometrium, Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT05375136
- Testing
- Non-interventional
- Where
- 19 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- Eisai Korea Inc.
Breast Cancer, Small Cell Lung Cancer
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity…
- Conditions
- Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT06257264
- Testing
- BG-68501, Fulvestrant, BGB-43395
- Where
- 24 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- BeiGene
Uterine Cancer
Insights Into Participating in Studies for Uterine Cancer
Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this trial so that it may collect a variety of data about uterine cancer clinical study…
- Trial name
- NCT05998811
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Fibroid Uterus, Leiomyoma
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
The objective of this study is to determine the safety and efficacy effects of two doses of asoprisnil (10 mg and 25 mg) compared with placebo when administered daily for 6 months to premenopausal subjects with symptomatic…
- Conditions
- Fibroid Uterus, Leiomyoma, Menorrhagia, Metrorrhagia
- Trial name
- NCT00152256
- Testing
- Asoprisnil
- Volunteers
- 239 people
- Sponsor
- Abbott
Cervical Cancer, Endometrial Cancer
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory Cervical and…
- Conditions
- Cervical Cancer, Endometrial Cancer, Advanced Cancer
- Trial name
- NCT05812677
- Testing
- Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Solid Tumors
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell…
- Trial name
- NCT03006887
- Testing
- lenvatinib, pembrolizumab
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Eisai Co., Ltd.
Uterine Leiomyomata (Fibroids)
Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 in Japanese Postmenopausal Women
The primary purpose of this study is to assess the safety and tolerability of ascending, multiple, oral doses of PRA-027 in Japanese postmenopausal women.
- Trial name
- NCT00826436
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Malignant Neoplasm
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with…
- Trial name
- NCT06894771
- Testing
- MK-4700, Pembrolizumab
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids…
- Trial name
- PRIMROSE 1 (NCT03070899)
- Testing
- OBE2109, Add-back
- Where
- 116 sites in United States
- Volunteers
- 526 people
- Sponsor
- ObsEva SA
Uterine Fibroids
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.
- Trial name
- NCT04567095
- Where
- United States
- Sponsor
- Allergan
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Colposcopy
Investigation of the Uterine Cervix Using CervicalMD
The purpose of this study is to demonstrate the CervicalMD device's ability to collect digital imagery suitable for a colposcopy examination.
- Trial name
- NCT00839475
- Volunteers
- 26 people
- Sponsor
- STI-Medical Systems
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Cervical Cancer
A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
This is a single-arm, open-label, multicentre, phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.All enrolled patients will receive the treatment with HLX10 combined…
- Trial name
- NCT04150575
- Testing
- HLX10+Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Henlius Biotech